Therapeutic developments in pancreatic cancer: current and future perspectives
The overall 5-year survival for pancreatic cancer has changed little over the past few
decades, and pancreatic cancer is predicted to be the second leading cause of cancer …
decades, and pancreatic cancer is predicted to be the second leading cause of cancer …
Neoadjuvant treatment in pancreatic cancer
A Oba, F Ho, QR Bao, MH Al-Musawi… - Frontiers in …, 2020 - frontiersin.org
Thanks to the development of modern chemotherapeutic regimens, survival after surgery for
pancreatic ductal adenocarcinoma (PDAC) has improved and pancreatologists worldwide …
pancreatic ductal adenocarcinoma (PDAC) has improved and pancreatologists worldwide …
Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients
T Hackert, M Sachsenmaier, U Hinz… - Annals of …, 2016 - journals.lww.com
Objective: For patients with locally advanced and unresectable pancreatic cancer (PDAC),
neodadjuvant treatment and consecutive surgical exploration have been studied during the …
neodadjuvant treatment and consecutive surgical exploration have been studied during the …
肝衰竭诊治指南(2024 年版).
李兰娟， 韩涛 - Journal of Clinical Hepatology/Linchuang …, 2024 - search.ebscohost.com
肝内胆管癌(ICC) 是一种高度恶性的胆道肿瘤, 其中早发性ICC (EOICC) 是指确诊年龄≤ 50
岁的ICC, 但通常具有更晚的临床分期, 更显著的生物学侵袭性. 目前EOICC …
岁的ICC, 但通常具有更晚的临床分期, 更显著的生物学侵袭性. 目前EOICC …
Pancreatic cancer
Pancreatic cancer is a major cause of cancer-associated mortality, with a dismal overall
prognosis that has remained virtually unchanged for many decades. Currently, prevention or …
prognosis that has remained virtually unchanged for many decades. Currently, prevention or …
Mechanisms of PDAC subtype heterogeneity and therapy response
E Espinet, L Klein, E Puré, SK Singh - Trends in Cancer, 2022 - cell.com
Pancreatic ductal adenocarcinoma (PDAC) is clinically challenging due to late diagnosis
and resistance to therapy. Two major PDAC subtypes have been defined based on …
and resistance to therapy. Two major PDAC subtypes have been defined based on …
Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: an intention to treat analysis
A Barenboim, G Lahat, R Geva, I Nachmany… - European Journal of …, 2018 - Elsevier
Objective To assess clinical and pathologic efficacy of neoadjuvant FOLFIRINOX for locally
advanced (LAPC) and borderline resectable pancreatic cancer (BRPC). Methods Patients …
advanced (LAPC) and borderline resectable pancreatic cancer (BRPC). Methods Patients …
Surgery for pancreatic cancer: current controversies and challenges
M Karunakaran, SG Barreto - Future Oncology, 2021 - Taylor & Francis
Two areas that remain the focus of improvement in pancreatic cancer include high post-
operative morbidity and inability to uniformly translate surgical success into long-term …
operative morbidity and inability to uniformly translate surgical success into long-term …
Optimizing indications for conversion surgery based on analysis of 454 consecutive Japanese cases with unresectable pancreatic cancer who received modified …
Y Ushida, Y Inoue, A Oba, T Mie, H Ito, Y Ono… - Annals of Surgical …, 2022 - Springer
Background The prognosis of initially unresectable pancreatic cancer (UR-PC) has
improved since the introduction of FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel …
improved since the introduction of FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel …
R0 resection following chemo (radio) therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO …
R Fietkau, R Grützmann, UA Wittel, RS Croner… - Strahlentherapie und …, 2021 - Springer
Purpose Chemotherapy with or without radiotherapy is the standard in patients with initially
nonmetastatic unresectable pancreatic cancer. Additional surgery is in discussion. The …
nonmetastatic unresectable pancreatic cancer. Additional surgery is in discussion. The …